metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mUC - L2 - all population metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - all population
versus Standard of Care (SoC)
	atezolizumab alone
	IMvigor-211 (all population), 2018 Lancet 2018;391:748-757 Eur Urol 2021 Apr 23;S0302-2838(21)00230-X. NCT02302807	RCT	mUC - L2 - all population	atezolizumab	chemotherapy	patients with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen patients had received no more than two previous lines of therapy and had progressed during or following one or more platinum-containing regimens for metastatic urothelial carcinoma (or neoadjuvant or adjuvant therapy with progression)	467 / 464	some concern	suggested	suggested 15 % decrease in deaths (OS) (PE) suggested 18 % decrease in deaths (OS) (extension)
	pembrolizumab alone
	KEYNOTE-045 (all population), 2017 N Engl J Med 2017;376:1015-1026 Urologe A 2015; 54:1287-90 Int. J. Clin. Oncol. 2020; 25:165-174 Ann. Oncol. 2019; 30:970-976 J Clin Oncol 2018 Jun 1;36(16):1579-1587. NCT02256436	RCT	mUC - L2 - all population	pembrolizumab	chemotherapy (ICC) : paclitaxel, docetaxel, or vinflunine	patients with advanced urothelial carcinoma that progressed during or after the receipt of platinumbased chemotherapy treated as second-line therapy	270 / 272	some concern	conclusif	demonstrated 27 % decrease in deaths (OS) (PE) inconclusive 2 % decrease in progression or deaths (PFS) (PE) suggested 30 % decrease in deaths (OS) (extension) demonstrated 1.1-fold increase in objective responses (ORR) (PE) more...
mUC - L2 - PDL1 positive metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - PDL1 positive
versus Standard of Care (SoC)
	atezolizumab alone
	IMvigor-211 (PDL1>5%), 2018 Lancet 2018;391:748-757 Eur Urol 2021 Apr 23;S0302-2838(21)00230-X. NCT02302807	RCT	mUC - L2 - PDL1 positive	atezolizumab	chemotherapy	patients with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen patients had received no more than two previous lines of therapy and had progressed during or following one or more platinum-containing regimens for metastatic urothelial carcinoma (or neoadjuvant or adjuvant therapy with progression)	116 / 118	some concern	inconclusive	inconclusive 13 % decrease in deaths (OS) (PE)
	IMvigor-211 (PDL1>1%), 2018 Lancet 2018;391:748-757 Eur Urol 2021 Apr 23;S0302-2838(21)00230-X. NCT02302807	RCT	mUC - L2 - PDL1 positive	atezolizumab	chemotherapy	patients with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen patients had received no more than two previous lines of therapy and had progressed during or following one or more platinum-containing regimens for metastatic urothelial carcinoma (or neoadjuvant or adjuvant therapy with progression	316 / 309	some concern	suggested	inconclusive 13 % decrease in deaths (OS) (PE)
	pembrolizumab alone
	KEYNOTE-045 (PDL1 CPS >10%), 2017 N Engl J Med 2017;376:1015-1026 Urologe A 2015; 54:1287-90 Int. J. Clin. Oncol. 2020; 25:165-174 Ann. Oncol. 2019; 30:970-976 NCT02256436	RCT	mUC - L2 - PDL1 positive	pembrolizumab	chemotherapy (ICC)	as second-line therapy in patients with advanced urothelial carcinoma that progressed during or after the receipt of platinumbased chemotherapy.=> only PDL1 CPS >10%	74 / 90	some concern	conclusif	demonstrated 43 % decrease in deaths (OS) (PE) inconclusive 11 % decrease in progression or deaths (PFS) (PE)